Jonathan C Fox bought $199k of EWTX
director at Edgewise Therapeutics, Inc.. 10,700 shares at an average of $18.64, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +15RoleDirector
- +12Trade size$199k at market
- +10Relative to holdingsHoldings up 82%
- +8Price context39% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001655016-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | POpen-market purchase Common Stock | +10,700 | $18.64 | $199k | 23,702 | Nov 13, 2025 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $685k 21,338 shares | -69% | |
| 33Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $507k 16,358 shares | -63% | |
| 25Weak | Edgewise Therapeutics, Inc. | Badreddin Edris director | $3.4M 115,471 shares | -85% | |
| 45Moderate | EWTXsell Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $2.1M 100,000 shares | -81% | |
| 60Notable | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $1.5M 100,000 shares | -81% | |
| 22Weak | Edgewise Therapeutics, Inc. | R Michael Carruthers Chief Financial Officer | $19k 1,428 shares | -2% | |
| 21Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $33k 2,491 shares | -10% | |
| 26Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $38k 2,862 shares | -10% | |
| 40Moderate | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $107k 7,972 shares | -21% | |
| 20Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $26k 1,907 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.